A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Study sponsor: Kodiak Sciences Inc · KOD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-11Actual
Enrollment · participants460Actual
Source updated2024-08-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.